Conditions: Pulmonary Arterial Hypertension
Keywords: Pulmonary Arterial Hypertension PAH EPITOME-1
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 2
Healthy volunteers: no

Brief summary:
This is an open-label, non-randomized extension to study AC-066A401. The study will assess safety and tolerability of ACT-385781A and Flolan (epoprostenol sodium) while providing a means for continuing treatment after ending participation in study AC-0066A401.

Detailed description:

Arms:
arm 1: ACT-385781A (Actelion Epoprostenol) arm 2: Flolan®

Interventions: intervention 1: ACT-385781A (Actelion Epoprostenol) intervention 2: Flolan®
Intervention descriptions: intervention 1: per Prescribing Information intervention 2: per Prescribing Information

Protocol document: